Johnson & Johnson stock draws a Moderate Buy consensus

Published on 09/29/2026 at 15:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock posted USD 25.31 billion revenue in Q2 2026, up 6.60 percent year over year. MarketBeat lists a USD 274.13 average target across 25 analysts on September 29, 2026.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground — Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 239.00 at Lang & Schwarz on September 29, 2026 at 3:08 p.m. CEST, with a minus 0.14 percent daily change versus the prior close of EUR 239.33. On September 29, 2026, MarketBeat reported a Moderate Buy consensus and an average 12-month price target of USD 274.13 from 25 analysts.

Analysts keep targets above USD 274

The consensus includes 18 Buy ratings, six Holds and one Strong Buy, according to MarketBeat. TD Cowen raised its target from USD 250.00 to USD 300.00 on July 13, 2026, while Wells Fargo lifted its target from USD 272.00 to USD 282.00 on August 3, 2026.

UBS reaffirmed a Buy rating on September 22, 2026, giving the current analyst picture a positive tilt even as the Lang & Schwarz quote sits below the average target in a different currency basis.

Q2 revenue rises to USD 25.31 billion

Johnson & Johnson reported Q2 2026 revenue of USD 25.31 billion, up 6.60 percent from the prior-year quarter, while adjusted EPS reached USD 2.90 versus USD 2.84 consensus, MarketBeat reported on September 17, 2026. Revenue also exceeded the USD 25.06 billion consensus estimate, adding a quantified earnings support to the analyst case.

Management set fiscal 2026 adjusted EPS guidance at USD 11.60-11.75. The next checkpoint is October 13, 2026, when Johnson & Johnson is scheduled to discuss third-quarter results, according to MarketBeat.

Market value stays near yearly high

Johnson & Johnson had a market capitalization of USD 655.4 billion as of September 28, 2026. Its 52-week range was USD 181.07 to USD 281.07, placing the latest primary-market quote near the upper end of that span and making forward earnings execution the central valuation test.

Johnson & Johnson stock holds its level

At Lang & Schwarz, Johnson & Johnson stock was trading at EUR 239.00 on September 29, 2026 at 3:08 p.m. CEST, with a minus 0.14 percent change versus the Lang & Schwarz prior close of EUR 239.33 on September 28, 2026.